The effect of combinated treatment of a metastatic HER2-positive stomach cancer
Trastuzumab in combination with standard chemotherapy has shown its effectiveness in treating HER2-positive metastatic gastric cancer. The median overall survival in its application is 16,8 months compared with 11,8 months when chemotherapy using alone. Authors demonstrate the case of the successful...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-12-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26960 |